Document is current
Any future updates will be listed below
-
Authors
van den Berg, K.
Wang, S.
Willems, J. M. W. E.
Creemers, G. J.
Roodhart, J. M. L.
Shkurti, J.
Burger, J. W. A.
Rutten, H. J. T.
Beets-Tan, R. G. H.
Nederend, J.
- License Information
-
More Information
Article History
Received: 2 August 2023
Revised: 4 October 2023
Accepted: 9 October 2023
First Online: 29 November 2023
Declarations
:
: JR: Advisory role for Merck-Serono, Pierre Fabre, Servier, BMS, Roche, Bayer, GSK (all payments to institution). Institutional scientific grants from Bristol Myers Squibb, Merck, Delphi, HUB4 Organoids, Cleara, Pierre Fabre, Servier, Xilis, GSK. The remaining authors have no competing interests to declare that are relevant to the content of this article.
: Written informed consent for participation was waived for this study.
: This study was evaluated by the Medical Research Ethics Committees United-Nieuwegein (registration number W20.294). The study was not subject to the Medical Research Involving Human Subjects Act.
